Ascletis Pharma Inc Cash Flow-to-Debt Ratio
Ascletis Pharma Inc cash flow-to-debt ratio. Ascletis Pharma Inc (2VJ) has a Cash Flow-to-Debt Ratio of -0.37x as of June 2023, meaning its operating cash flow of €-33.98 Million could theoretically repay 0% of its total liabilities (€90.79 Million) in one year. See 2VJ free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Ascletis Pharma Inc (2016–2025)
Cash flow-to-debt ratio of Ascletis Pharma Inc from 2016 to 2025. Historical debt coverage capacity for Ascletis Pharma Inc across 10 annual periods. Also explore Ascletis Pharma Inc net asset momentum to track the company's year-over-year net asset growth rate.
Ascletis Pharma Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Ascletis Pharma Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Ascletis Pharma Inc. For the full cash flow conversion analysis, see cash flow conversion of Ascletis Pharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | €-416.78 Million | €132.26 Million | ▼ -46.1% |
| 2024 | -2.16x | €-341.58 Million | €158.41 Million | ▼ -43.5% |
| 2023 | -1.50x | €-223.79 Million | €148.94 Million | ▼ -23.6% |
| 2022 | -1.22x | €-142.45 Million | €117.16 Million | ▲ +16.5% |
| 2021 | -1.46x | €-146.93 Million | €100.89 Million | ▼ -46.5% |
| 2020 | -0.99x | €-84.91 Million | €85.42 Million | ▼ -36.6% |
| 2019 | -0.73x | €-74.34 Million | €102.17 Million | ▲ +24.5% |
| 2018 | -0.96x | €-96.59 Million | €100.19 Million | ▲ +40.9% |
| 2017 | -1.63x | €-198.06 Million | €121.42 Million | ▼ -1559.8% |
| 2016 | -0.10x | €-12.50 Million | €127.18 Million | — |